Recall Merck also tried to get an "improved niacin" by targeting the same receptor with MK-0354, which despite significant decreases in FFAs levels and absence of flushing failed to demonstrate effects on HDL/LDL-Cholesterol and TGs in phase II. Obviously, being a GPR109A receptor agonist isn't all.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.